CDK4/6 inhibition in advanced chordoma: final results of the NCT PMO-1601 trial
Although antitumor activity was modest, the trial met its primary endpoint. Molecularly tailored combination therapies should be considered in the future to improve efficacy.
Authors
- Oliver Sedlaczek (ORCID: https://orcid.org/0000-0002-8709-5481)
- Daniel Hübschmann (ORCID: https://orcid.org/0000-0002-6041-7049)
- Dirk Jäger
- Stefan Fröhling (ORCID: https://orcid.org/0000-0001-7907-4595)
- Christoph E. Heilig (ORCID: https://orcid.org/0000-0001-8869-1421)
- Maria‐Veronica Teleanu (ORCID: https://orcid.org/0000-0002-2176-6158)
- Sebastian Bauer (ORCID: https://orcid.org/0000-0001-5949-8120)
- Barbara Hutter (ORCID: https://orcid.org/0000-0002-9034-0329)
- Peter Horak (ORCID: https://orcid.org/0000-0003-4536-9306)
- C. Müller-Tidow
- Simon Kreutzfeldt (ORCID: https://orcid.org/0000-0003-3278-4586)
- Richard F. Schlenk (ORCID: https://orcid.org/0000-0003-2215-2059)
- Angelika Freitag
- Jude Al-Sabah (ORCID: https://orcid.org/0000-0003-2635-0423)
- Rainer Hamacher (ORCID: https://orcid.org/0000-0001-9655-1226)
- Verena I. Gaidzik
- Sebastian Pirmann
- Christof von Kalle (ORCID: https://orcid.org/0000-0001-9221-3297)
- Gerlinde Egerer (ORCID: https://orcid.org/0009-0005-0462-4165)
- Jennifer Hüllein
- Thomas F.E. Barth (ORCID: https://orcid.org/0000-0002-3379-6311)
- Burkhard Lehner (ORCID: https://orcid.org/0000-0002-6776-4801)
- Sandra S.L. Roldan Pinzon
- Herbert Süße
- R. Mayer-Steinacker
Institutions
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- Essen University Hospital (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (DE)
- University Hospital Ulm (DE)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105498
- Citations
- 1
- Primary Topic
- Cancer-related Molecular Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Deutsches Krebsforschungszentrum
- Astellas Pharma
- Deutschen Konsortium für Translationale Krebsforschung
- PharmaMar
- Daiichi Sankyo Europe